Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence

  • Kang, Seong Hee (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Cho, Hyeki (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Cho, Eun Ju (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Lee, Jeong-Hoon (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Yu, Su Jong (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Kim, Yoon Jun (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Yi, Nam-Joon (Department of Surgery, Seoul National University College of Medicine) ;
  • Lee, Kwang-Woong (Department of Surgery, Seoul National University College of Medicine) ;
  • Suh, Kyung-Suk (Department of Surgery, Seoul National University College of Medicine) ;
  • Yoon, Jung-Hwan (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
  • Received : 2018.05.25
  • Accepted : 2018.07.18
  • Published : 2018.11.05
⟨ Previous Next ⟩

Abstract

Background: The role of sorafenib in patients with hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been rarely studied. The aim of this study was to evaluate the efficacy of sorafenib in post-LT era. Methods: Consecutive patients with post-transplant HCC recurrence not eligible to resection or locoregional therapy were included. Patients receiving best supportive care (BSC) until 2007 were compared with those treated by sorafenib thereafter. Results: Of a total of 65 patients, 20 patients received BSC and 45 received sorafenib. Clinical characteristics were similar between two groups except that sorafenib group received tacrolimus and mammalian target-of-rapamycin inhibitors more frequently than BSC group. Treatment with sorafenib conferred a survival advantage as compared with BSC for survival after recurrence (median, 14.2 vs. 6.8 months; P = 0.01). In multivariate analyses, high serum ${\alpha}$-fetoprotein level, synchronous intrahepatic recurrence and distant metastasis at the time of recurrence, and BSC were independently associated with poorer survival after recurrence. Sorafenib treatment was associated with better survival after recurrence as compared with BSC (hazard ratio, 0.25; 95% confidence interval, 0.10-0.62; P = 0.002). In addition, sorafenib group showed tolerable toxicity in the post-transplant setting. Conclusion: Sorafenib may be beneficial in patients with post-transplant HCC recurrence.

Keywords

References

  1. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6):1394-403. https://doi.org/10.1053/jhep.2001.24563
  2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-9. https://doi.org/10.1056/NEJM199603143341104
  3. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13(1):e11-22. https://doi.org/10.1016/S1470-2045(11)70175-9
  4. Hollebecque A, Decaens T, Boleslawski E, Mathurin P, Duvoux C, Pruvot FR, et al. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol 2009;33(5):361-9. https://doi.org/10.1016/j.gcb.2009.02.036
  5. Davis E, Wiesner R, Valdecasas J, Kita Y, Rossi M, Schwartz M. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011;17 Suppl 2:S162-6. https://doi.org/10.1002/lt.22361
  6. European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64(2):433-85. https://doi.org/10.1016/j.jhep.2015.10.006
  7. Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22(3):309-18. https://doi.org/10.3350/cmh.2016.0042
  8. Wang P, Li H, Shi B, Que W, Wang C, Fan J, et al. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study. Oncotarget 2016;7(23):35071-83.
  9. de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol 2015;21(39):11185-98. https://doi.org/10.3748/wjg.v21.i39.11185
  10. Park MS, Lee KW, Yi NJ, Choi YR, Kim H, Hong G, et al. Optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinoma. J Korean Med Sci 2014;29(10):1360-6. https://doi.org/10.3346/jkms.2014.29.10.1360
  11. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69(5):781-9. https://doi.org/10.1097/00007890-200003150-00018
  12. Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, et al. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 2014;20(2):192-203. https://doi.org/10.3350/cmh.2014.20.2.192
  13. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10(4):534-40. https://doi.org/10.1002/lt.20128
  14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90. https://doi.org/10.1056/NEJMoa0708857
  15. Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013;59(1):59-66. https://doi.org/10.1016/j.jhep.2013.02.026
  16. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Duber C, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 2012;44(5):432-7. https://doi.org/10.1016/j.dld.2011.12.009
  17. Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Vigano R, Cordone G, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013;25(2):180-6. https://doi.org/10.1097/MEG.0b013e328359e550
  18. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2. https://doi.org/10.1002/hep.24199
  19. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18(1):45-52. https://doi.org/10.1002/lt.22434
  20. de'Angelis N, Landi F, Nencioni M, Palen A, Lahat E, Salloum C, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant 2016;26(4):348-55. https://doi.org/10.1177/1526924816664083
  21. Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci 2013;20(3):342-7. https://doi.org/10.1007/s00534-012-0528-4
  22. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 2015;9(3):267-317. https://doi.org/10.5009/gnl14460
  23. Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant 2016;21(2):231-7. https://doi.org/10.1097/MOT.0000000000000294
  24. Hong SK, Lee KW, Kim HS, Yoon KC, Yi NJ, Suh KS. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr 2016;5(6):453-60. https://doi.org/10.21037/hbsn.2016.08.07
  25. Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014;97(1):71-7. https://doi.org/10.1097/TP.0b013e3182a68953
  26. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant 2013;27(1):140-7. https://doi.org/10.1111/ctr.12031
  27. Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl 2009;15(12):1861-6. https://doi.org/10.1002/lt.21940
  28. Man K, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003;237(2):256-64. https://doi.org/10.1097/01.SLA.0000048976.11824.67
  29. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S277-82. https://doi.org/10.1053/j.gastro.2004.09.042
  30. Alsina AE, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, et al. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. Am Surg 2014;80(7):680-4.
  31. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010;52(5):771-5. https://doi.org/10.1016/j.jhep.2010.01.025
  32. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008;14(16):5124-30. https://doi.org/10.1158/1078-0432.CCR-07-4774
  33. Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011;10(6):1007-17. https://doi.org/10.1158/1535-7163.MCT-10-0666
  34. Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol 2016;27(5):856-61. https://doi.org/10.1093/annonc/mdw054
  35. Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016;100(1):116-25. https://doi.org/10.1097/TP.0000000000000965

Cited by

  1. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation vol.33, pp.45, 2018, https://doi.org/10.3346/jkms.2018.33.e286
  2. Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria? vol.72, pp.4, 2020, https://doi.org/10.1002/hep.31285
  3. Targeted therapy for hepatocellular carcinoma vol.5, pp.None, 2020, https://doi.org/10.1038/s41392-020-00264-x
  4. Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma vol.14, pp.1, 2018, https://doi.org/10.3390/ph14010046
  5. Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort vol.41, pp.4, 2018, https://doi.org/10.1111/liv.14736